SecBot SecBot
PRESS-RELEASE ·Filed May 29, 2026

REPL

Replimune, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a major de-risking event for REPL. The FDA's commitment to prioritize review significantly increases the probability of approval. Traders should watch for the BLA resubmission confirmation and any PDUFA date assignment.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.69
T+0 close · May 29, 2026 · via day close
Latest settled
+69.28%
T+60 · $14.71
Vs SPY
+68.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 29 $8.69entry
  2. T+1 · 6mo ago +3.57%α +3.29% · $9.00
  3. T+5 · 6mo ago +14.84%α +15.14% · $9.98
  4. T+20 · 5mo ago +28.88%α +30.68% · $11.20
  5. T+60 · 3mo ago +69.28%α +68.09% · $14.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Replimune announced alignment with the FDA on a path forward for resubmission of the RP1 BLA for advanced melanoma, with the FDA committing to prioritize review. This is a significant regulatory de-risking event for a clinical-stage biotech with no approved products, transforming the company's outlook.

Key Facts

  • Replimune and FDA aligned on path forward for RP1 BLA resubmission for advanced melanoma
  • BLA resubmission expected in coming days; FDA will treat as urgent matter and prioritize review
  • RP1 is Replimune's lead product candidate; company has no approved products
  • Approximately 8,500 advanced melanoma deaths annually; ~50% of patients fail checkpoint inhibitor therapy
  • BLA supported by IGNYTE clinical trial data

Financial Impact

Transformative for a ~$386M market cap clinical-stage biotech; FDA approval would open a multi-hundred-million to billion-dollar market opportunity in advanced melanoma

revenuemarket capcash runway

Risk Factors

  • FDA may still issue a Complete Response Letter after review
  • Clinical data from IGNYTE trial may not meet approval standards
  • Competition from other melanoma therapies could limit commercial potential
  • Company has no approved products and limited cash runway

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
8% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303541

Track record

32 reports on REPL

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  5. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  6. Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  7. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
  8. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
  10. Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026